Targeting Nuclear Export Proteins in Multiple Myeloma Therapy Nicholas TheodoropoulosGuido LancmanAjai Chari Review Article 19 October 2020 Pages: 697 - 708
Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data Dawid SigorskiEwa Iżycka-ŚwieszewskaLubomir Bodnar Review Article Open access 12 October 2020 Pages: 709 - 722
Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis Jacques RaphaelCory LefebvrePhillip S Blanchette Systematic Review 05 November 2020 Pages: 723 - 732
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Julie G. FisherDavid TaitRichard L. Schilsky Original Research Article 22 October 2020 Pages: 733 - 741
Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Tareq Al BaghdadiElizabeth Garrett-MayerRichard L. Schilsky Original Research Article 17 October 2020 Pages: 743 - 750
Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry Li Chia ChongJennifer E. HardinghamTimothy J. Price Original Research Article 17 October 2020 Pages: 751 - 757
A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping Baptiste LouveauFanélie JouenneSamia Mourah Original Research Article 05 November 2020 Pages: 759 - 771
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma Giulia OrsiFrancesco TovoliAndrea Casadei-Gardini Original Research Article 12 October 2020 Pages: 773 - 785
SB8: A Bevacizumab Biosimilar Yahiya Y. Syed Adis Biosimilar Brief Open access 18 November 2020 Pages: 787 - 790
Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer Lesley J. Scott Adis Drug Evaluation Open access 25 November 2020 Pages: 791 - 799
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study Luca FaloppiMarco PuzzoniMario Scartozzi Correction 10 November 2020 Pages: 801 - 802
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer Ramesh K. RamanathanDaniel D. Von HoffKlaus Mross Correction Open access 27 October 2020 Pages: 803 - 803
Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3 Diana LüftnerGary H. LymanMinji Seo Correction 20 October 2020 Pages: 805 - 805
Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product Dietger NiederwieserCaroline HammDavid Chien Correction Open access 12 November 2020 Pages: 807 - 807
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma Giulia OrsiFrancesco TovoliAndrea Casadei-Gardini Correction 28 October 2020 Pages: 809 - 810
